MedDataX Logo

A Drug Safety and Dose-exploratory Clinical Study of Azvudine Tablets in Patients Who Have Not Received Anti-HIV Treatment

NCT ID: NCT04109183

Last Updated: 2019-09-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

172 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-10

Study Completion Date

2019-03-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this trial was to evaluate the safety and preliminary evaluation of Azvudine tablets (FNC) in combination with reverse transcriptase inhibitors therapy in treatment-naive patients with HIV infection.; the secondary objective is to explore the effective dose of clinical use of Azvudine (FNC) tablets .

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Azvudine (FNC), a new class I drug with independent intellectual property rights, is a novel nucleoside reverse transcriptase inhibitor with good inhibitory activity against HIV-1 and obtained the National Medical Products Administration(NMPA) approved for clinical research.

In this trial, 172 patients who had not received anti-HIV treatment were enrolled, including FNC4mg group, FNC3mg group, FNC2mg group, and 3TC control group, 43 cases, 5 research centers, and each research center was simultaneously engaged and competing. The enrolled subjects underwent 7 visits including baseline visits, and HIV -1RNA and CD4 cell counts were tested and statistically analyzed for each visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

AIDS

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

HIV/AIDS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

a multicenter, randomized, double-blind, double-simulation, positive control trial.
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors
This experiment used a block randomization method, and each research center competed for inclusion. The SAS software (9.3 or above) was used to generate a random table and the corresponding treatment group for the random table. The clinical trial electronic central stochastic system (DAS for IWRS) was used to assign random numbers.Blind bottom sealed preservation, respectively sealed by the sponsor and clinical research unit.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active Comparator: FNC 2 mg+ TDF+EFV

Group Type EXPERIMENTAL

The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.

Intervention Type DRUG

The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.

Active Comparator: FNC 3 mg+ TDF+EFV

Group Type EXPERIMENTAL

The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.

Intervention Type DRUG

The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.

Active Comparator: FNC 4 mg+ TDF+EFV

Group Type EXPERIMENTAL

The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.

Intervention Type DRUG

The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.

Postive Comparator: 3TC+ TDF+EFV

Group Type EXPERIMENTAL

The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.

Intervention Type DRUG

The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.

The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1.18-65 years old, regardless of gender; 2.Confirmed HIV positive with a report; 3.Have not received anti-hiv antiviral treatment; 4.HIV viral load ≥1000 copies/mL; 5.Who have no recent family planning and agree to take effective non-drug contraceptive measures during the trial period and within 3 months after the end of administration; 6.The subjects could fully understand the purpose, nature, method and possible adverse reactions of the test, and voluntarily participate in and sign the informed consent.

Exclusion Criteria

1. Patients who have received anti-HIV treatment;
2. Suffering from a serious opportunistic infection or opportunistic tumor;
3. Abnormal blood routine examination (white blood cells \<3 × 109 / L, hemoglobin \<90g / L, neutrophils \<1.5 × 109 / L, platelets \<75 × 109 / L);
4. Have a definite liver disease (hepatitis B surface antigen/HCV antibody positive), or abnormal liver function test (alanine aminotransferase and/or aspartate aminotransferase exceeds the upper limit of normal value by 3 times, or total bilirubin exceeds the upper limit of normal value 2 times);
5. Renal insufficiency (glomerular filtration rate \<70ml/min, or creatinine above the upper limit of normal);
6. Now suffering from more serious chronic diseases, metabolic diseases (such as diabetes), neurological and psychiatric diseases;
7. Has suffered from pancreatitis;
8. Women during pregnancy and lactation;
9. allergic constitution or known to be allergic to the pharmaceutical ingredients and the basic drugs prescribed in this program;
10. Suspect or determine the history of alcohol and drug abuse;
11. Participated in other drug clinical trials (excluding Chinese medicine) within the first three months of screening;
12. Other factors that are not suitable for entering the trial.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beijing YouAn Hospital

OTHER

Sponsor Role collaborator

Peking Union Medical College Hospital

OTHER

Sponsor Role collaborator

Beijing Ditan Hospital

OTHER

Sponsor Role collaborator

Guangzhou 8th People's Hospital

OTHER

Sponsor Role collaborator

The Sixth People's Hospital of Zhengzhou

OTHER

Sponsor Role collaborator

Henan Genuine Biotech Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beijing YouAn Hospital, Capital Medical University.

Beijing, Beijing Municipality, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GQ-FNC-201

Identifier Type: -

Identifier Source: org_study_id